Kura Oncology, Inc. recently shared preliminary data from its KOMET-007 trial. This Phase 1 test involved escalating doses of Ziftomenib, their menin inhibitor, in combination with standard treatments for specific varieties of acute myeloid leukemia (AML).
During the period from July 2023 to November 2023, early data from 20 patients showed no adverse reactions to a daily dose of 200 mg of Ziftomenib. No instances of differentiation syndrome were reported.
As of January 11, 2024, all patients newly diagnosed with AML who underwent treatment with Ziftomenib and a combination of cytarabine and daunorubicin saw a full recovery with complete remission. As of this date, the trial retains 80% of these patients, which includes 100% of those with NPM1-m.
Kura Oncology further reported that the 200 mg Ziftomenib dose has been approved for use in R/R ven/aza cohorts, and they are currently enrolling patients for a 400 mg dosage test. Kura Oncology CEO, Troy Wilson, expressed optimism about the potential of Ziftomenib to revolutionize treatment outcomes given its ability to target foundational mutations in approximately 50% of AML cases. Wilson also anticipates that all 85 will be enrolled in KOMET-001, their Phase 2 Ziftomenib trial for R/R NPM1-m AML patients, by the mid of this year.
